Transferrin therapy ameliorates disease in Β-thalassemic mice

Huihui Li, Anne C. Rybicki, Sandra M. Suzuka, Leni Von Bonsdorff, William Breuer, Charles B. Hall, Z. Ioav Cabantchik, Eric E. Bouhassira, Mary E. Fabry, Yelena Z. Ginzburg

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Individuals with Β-thalassemia develop progressive systemic iron overload, resulting in high morbidity and mortality. These complications are caused by labile plasma iron, which is taken up by parenchymal cells in a dysregulated manner; in contrast, erythropoiesis depends on transferrin-bound iron uptake via the transferrin receptor. We hypothesized that the ineffective erythropoiesis and anemia observed in Β-thalassemia might be ameliorated by increasing the amount of circulating transferrin. We tested the ability of transferrin injections to modulate iron metabolism and erythropoiesis in Hbb th1/th1 mice, an experimental model of Β-thalassemia. Injected transferrin reversed or markedly improved the thalassemia phenotype in these mice. Specifically, transferrin injections normalized labile plasma iron concentrations, increased hepcidin expression, normalized red blood cell survival and increased hemoglobin production; this treatment concomitantly decreased reticulocytosis, erythropoietin abundance and splenomegaly. These results indicate that transferrin is a limiting factor contributing to anemia in these mice and suggest that transferrin therapy might be beneficial in human Β-thalassemia.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
JournalNature Medicine
Volume16
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Transferrin
Thalassemia
Iron
Erythropoiesis
Therapeutics
Anemia
Reticulocytosis
Hepcidins
Plasmas
Injections
Transferrin Receptors
Iron Overload
Splenomegaly
Erythropoietin
Metabolism
Cell Survival
Hemoglobins
Blood
Theoretical Models
Erythrocytes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Li, H., Rybicki, A. C., Suzuka, S. M., Von Bonsdorff, L., Breuer, W., Hall, C. B., ... Ginzburg, Y. Z. (2010). Transferrin therapy ameliorates disease in Β-thalassemic mice. Nature Medicine, 16(2), 177-182. https://doi.org/10.1038/nm.2073

Transferrin therapy ameliorates disease in Β-thalassemic mice. / Li, Huihui; Rybicki, Anne C.; Suzuka, Sandra M.; Von Bonsdorff, Leni; Breuer, William; Hall, Charles B.; Cabantchik, Z. Ioav; Bouhassira, Eric E.; Fabry, Mary E.; Ginzburg, Yelena Z.

In: Nature Medicine, Vol. 16, No. 2, 02.2010, p. 177-182.

Research output: Contribution to journalArticle

Li, H, Rybicki, AC, Suzuka, SM, Von Bonsdorff, L, Breuer, W, Hall, CB, Cabantchik, ZI, Bouhassira, EE, Fabry, ME & Ginzburg, YZ 2010, 'Transferrin therapy ameliorates disease in Β-thalassemic mice', Nature Medicine, vol. 16, no. 2, pp. 177-182. https://doi.org/10.1038/nm.2073
Li H, Rybicki AC, Suzuka SM, Von Bonsdorff L, Breuer W, Hall CB et al. Transferrin therapy ameliorates disease in Β-thalassemic mice. Nature Medicine. 2010 Feb;16(2):177-182. https://doi.org/10.1038/nm.2073
Li, Huihui ; Rybicki, Anne C. ; Suzuka, Sandra M. ; Von Bonsdorff, Leni ; Breuer, William ; Hall, Charles B. ; Cabantchik, Z. Ioav ; Bouhassira, Eric E. ; Fabry, Mary E. ; Ginzburg, Yelena Z. / Transferrin therapy ameliorates disease in Β-thalassemic mice. In: Nature Medicine. 2010 ; Vol. 16, No. 2. pp. 177-182.
@article{42d89232b5c54be1881b2902facd785d,
title = "Transferrin therapy ameliorates disease in Β-thalassemic mice",
abstract = "Individuals with Β-thalassemia develop progressive systemic iron overload, resulting in high morbidity and mortality. These complications are caused by labile plasma iron, which is taken up by parenchymal cells in a dysregulated manner; in contrast, erythropoiesis depends on transferrin-bound iron uptake via the transferrin receptor. We hypothesized that the ineffective erythropoiesis and anemia observed in Β-thalassemia might be ameliorated by increasing the amount of circulating transferrin. We tested the ability of transferrin injections to modulate iron metabolism and erythropoiesis in Hbb th1/th1 mice, an experimental model of Β-thalassemia. Injected transferrin reversed or markedly improved the thalassemia phenotype in these mice. Specifically, transferrin injections normalized labile plasma iron concentrations, increased hepcidin expression, normalized red blood cell survival and increased hemoglobin production; this treatment concomitantly decreased reticulocytosis, erythropoietin abundance and splenomegaly. These results indicate that transferrin is a limiting factor contributing to anemia in these mice and suggest that transferrin therapy might be beneficial in human Β-thalassemia.",
author = "Huihui Li and Rybicki, {Anne C.} and Suzuka, {Sandra M.} and {Von Bonsdorff}, Leni and William Breuer and Hall, {Charles B.} and Cabantchik, {Z. Ioav} and Bouhassira, {Eric E.} and Fabry, {Mary E.} and Ginzburg, {Yelena Z.}",
year = "2010",
month = "2",
doi = "10.1038/nm.2073",
language = "English (US)",
volume = "16",
pages = "177--182",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Transferrin therapy ameliorates disease in Β-thalassemic mice

AU - Li, Huihui

AU - Rybicki, Anne C.

AU - Suzuka, Sandra M.

AU - Von Bonsdorff, Leni

AU - Breuer, William

AU - Hall, Charles B.

AU - Cabantchik, Z. Ioav

AU - Bouhassira, Eric E.

AU - Fabry, Mary E.

AU - Ginzburg, Yelena Z.

PY - 2010/2

Y1 - 2010/2

N2 - Individuals with Β-thalassemia develop progressive systemic iron overload, resulting in high morbidity and mortality. These complications are caused by labile plasma iron, which is taken up by parenchymal cells in a dysregulated manner; in contrast, erythropoiesis depends on transferrin-bound iron uptake via the transferrin receptor. We hypothesized that the ineffective erythropoiesis and anemia observed in Β-thalassemia might be ameliorated by increasing the amount of circulating transferrin. We tested the ability of transferrin injections to modulate iron metabolism and erythropoiesis in Hbb th1/th1 mice, an experimental model of Β-thalassemia. Injected transferrin reversed or markedly improved the thalassemia phenotype in these mice. Specifically, transferrin injections normalized labile plasma iron concentrations, increased hepcidin expression, normalized red blood cell survival and increased hemoglobin production; this treatment concomitantly decreased reticulocytosis, erythropoietin abundance and splenomegaly. These results indicate that transferrin is a limiting factor contributing to anemia in these mice and suggest that transferrin therapy might be beneficial in human Β-thalassemia.

AB - Individuals with Β-thalassemia develop progressive systemic iron overload, resulting in high morbidity and mortality. These complications are caused by labile plasma iron, which is taken up by parenchymal cells in a dysregulated manner; in contrast, erythropoiesis depends on transferrin-bound iron uptake via the transferrin receptor. We hypothesized that the ineffective erythropoiesis and anemia observed in Β-thalassemia might be ameliorated by increasing the amount of circulating transferrin. We tested the ability of transferrin injections to modulate iron metabolism and erythropoiesis in Hbb th1/th1 mice, an experimental model of Β-thalassemia. Injected transferrin reversed or markedly improved the thalassemia phenotype in these mice. Specifically, transferrin injections normalized labile plasma iron concentrations, increased hepcidin expression, normalized red blood cell survival and increased hemoglobin production; this treatment concomitantly decreased reticulocytosis, erythropoietin abundance and splenomegaly. These results indicate that transferrin is a limiting factor contributing to anemia in these mice and suggest that transferrin therapy might be beneficial in human Β-thalassemia.

UR - http://www.scopus.com/inward/record.url?scp=76349118307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349118307&partnerID=8YFLogxK

U2 - 10.1038/nm.2073

DO - 10.1038/nm.2073

M3 - Article

C2 - 20098432

AN - SCOPUS:76349118307

VL - 16

SP - 177

EP - 182

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -